Baseline Inflammation Levels Influenced Whether Cannabis Helped Anxiety and Sleep

While cannabis use did not change cytokine concentrations over four weeks, baseline inflammation moderated outcomes. People with higher baseline inflammation responded differently to different cannabis chemovars. CBD-dominant products produced more consistent improvements in negative affect and sleep quality, while THC-associated improvements varied depending on the person's inflammatory state.

Participants with mild or greater anxiety (n=147) were assigned to one of three cannabis chemovars (THC+CBD, THC-only, CBD-only) for 4 weeks of ad libitum use and compared to an anxiety control group (n=24). Depression, anxiety, stress (DASS-21), sleep quality (PSQI), and plasma cytokines were measured at baseline and week 4.

This is among the first studies to show that a person's inflammatory profile may predict whether cannabis will help their anxiety and sleep. It suggests a possible biological reason why cannabis works for some people with anxiety but not others.

Personalized medicine approaches to cannabis are in their infancy. This study suggests that measuring inflammation could eventually help predict who will benefit from cannabis for anxiety and which chemovar to recommend.

Non-randomized assignment to chemovars. Ad libitum use means dosing varied. Small control group (24). Four-week follow-up may be too short for stable effects. Cannot determine optimal THC:CBD ratios from this design.